Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

NCT ID: NCT01125917

Last Updated: 2012-09-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

354 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS). Subjects begin the extension phase on BTDS 5 mcg/h and may up- or down-titrate the dose \[up to BTDS 20 micrograms (mcg) / hour (h)\] depending on adequate pain relief and tolerability.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Back Pain Lower Back Chronic

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Low back pain Opioid Transdermal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BTDS

Buprenorphine transdermal patch

Group Type EXPERIMENTAL

Buprenorphine transdermal patch

Intervention Type DRUG

Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.

Buprenorphine transdermal patch

Intervention Type DRUG

Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.

Buprenorphine transdermal patch

Intervention Type DRUG

Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buprenorphine transdermal patch

Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.

Intervention Type DRUG

Buprenorphine transdermal patch

Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.

Intervention Type DRUG

Buprenorphine transdermal patch

Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Butrans™ Butrans™ Butrans™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who completed all visits of the double-blind phase on study drug, and subjects who discontinued study drug due to lack of therapeutic effect in the double-blind phase but completed all visits of the double-blind phase off study drug are eligible to enroll in the extension phase.
* For subjects entering the extension, 4 electrocardiograms (ECGs) are required at entry if none were collected prior to randomization while on BTDS 20. NOTE: Subjects with any 1 QT data corrected for heart rate using the Fridericia formula (QTcF) interval ≥ 500 milliseconds (msec) would be discontinued from the extension phase

Exclusion Criteria

* Subjects requiring long-acting opioid analgesics \[once- or twice-daily dosing with a every (q) 24 hours (h) or q12h drug\] or transdermal fentanyl during the extension phase should be discontinued from the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Purdue Pharma LP

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deborah L Steiner, MD, MS

Role: STUDY_DIRECTOR

Purdue Pharma LP

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham Pain Center

Birmingham, Alabama, United States

Site Status

Arthritis Clinical Intervention Program

Birmingham, Alabama, United States

Site Status

Winston Physician Services, Inc

Haleyville, Alabama, United States

Site Status

Arizona Research Center Inc

Phoenix, Arizona, United States

Site Status

Radiant Research

Phoenix, Arizona, United States

Site Status

Advanced Clinical Therapeutics

Tucson, Arizona, United States

Site Status

Hot Springs Pain Clinic

Hot Springs, Arkansas, United States

Site Status

NuLife Clinical Research, Inc.

Anaheim, California, United States

Site Status

Lovelace Scientific Resources

Beverly Hills, California, United States

Site Status

Northern California Research Corp

Carmichael, California, United States

Site Status

International Clinical Research Network

Chula Vista, California, United States

Site Status

Shreenath Clinical Service

Fountain Valley, California, United States

Site Status

U of Calif at Davis, Med Ctr, Pain Management Center

Sacramento, California, United States

Site Status

Accelovance

San Diego, California, United States

Site Status

Southern Colorado Clinic

Pueblo, Colorado, United States

Site Status

Chiefland Medical Center

Chiefland, Florida, United States

Site Status

University Clinical Research Deland

DeLand, Florida, United States

Site Status

Drug Study Institute

Jupiter, Florida, United States

Site Status

Innovative Research of West Florida, Inc.

Largo, Florida, United States

Site Status

Renstar Medical

Ocala, Florida, United States

Site Status

Peninsula Research Inc.

Ormond Beach, Florida, United States

Site Status

The Arthritis Center

Palm Harbor, Florida, United States

Site Status

University Clinical Research, Inc.

Pembroke Pines, Florida, United States

Site Status

Gold Coast Research, LLC

Plantation, Florida, United States

Site Status

Palm Beach Research Center

West Palm Beach, Florida, United States

Site Status

Georgia Medical Research Institute

Marietta, Georgia, United States

Site Status

Atlanta Knee & Shoulder Clinic

Stockbridge, Georgia, United States

Site Status

Pain Care Boise

Boise, Idaho, United States

Site Status

Idaho Arthritis and Osteoporosis Center

Meridian, Idaho, United States

Site Status

Pain and Rehabilitation Clinic of Chicago

Chicago, Illinois, United States

Site Status

GFI Research Center

Evansville, Indiana, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Medical Associates Clinics

Dubuque, Iowa, United States

Site Status

Vince and Associates Clinical Research

Overland Park, Kansas, United States

Site Status

CTT, Inc.

Prairie Village, Kansas, United States

Site Status

Commonwealth Biomedical Research, LLC

Madisonville, Kentucky, United States

Site Status

New Orleans Clinical Trial Management Inc.

Metairie, Louisiana, United States

Site Status

Louisiana Research Associates, Inc.

New Orleans, Louisiana, United States

Site Status

Best Clinical Trials, LLC

New Orleans, Louisiana, United States

Site Status

Research Center of Louisiana

New Orleans, Louisiana, United States

Site Status

Sinai Hospital of Baltimore

Baltimore, Maryland, United States

Site Status

Future Care Studies

Springfield, Massachusetts, United States

Site Status

Rheumatology PC

Kalamazoo, Michigan, United States

Site Status

Lake Michigan Clinical Research & Consulting, Inc.

Saint Joseph, Michigan, United States

Site Status

Medex Healthcare Research Inc

St Louis, Missouri, United States

Site Status

HealthCare Research

St Louis, Missouri, United States

Site Status

Meridian Clinical Research, LLC

Omaha, Nebraska, United States

Site Status

Lovelace Scientific Resources

Henderson, Nevada, United States

Site Status

Pivotal Research Centers

North Las Vegas, Nevada, United States

Site Status

Research Across America

New York, New York, United States

Site Status

Pain and Orthopedic Neurology , Charlotte Spine Center,

Charlotte, North Carolina, United States

Site Status

Metrolina Medical Research

Charlotte, North Carolina, United States

Site Status

Triangle Orthopaedic Associates

Durham, North Carolina, United States

Site Status

Pharmquest

Greensboro, North Carolina, United States

Site Status

MedArk Clinical Research

Morgantown, North Carolina, United States

Site Status

Wake Research Associates, LLC

Raleigh, North Carolina, United States

Site Status

Center for Clinical Research

Winston-Salem, North Carolina, United States

Site Status

Odyssey Research

Bismarck, North Dakota, United States

Site Status

COR Clinical Research, LLC

Oklahoma City, Oklahoma, United States

Site Status

Associated Medical Services Inc

Oklahoma City, Oklahoma, United States

Site Status

Keystone Clinical Research

Altoona, Pennsylvania, United States

Site Status

Valley Pain Specialists

Bethlehem, Pennsylvania, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Central Pennsylvania Clinical Research

Mechanicsburg, Pennsylvania, United States

Site Status

BioMedical Research Associates

Shippensburg, Pennsylvania, United States

Site Status

University Orthopedics Center

State College, Pennsylvania, United States

Site Status

New England Center Clinical Research

Cranston, Rhode Island, United States

Site Status

Omega Medical Research

Warwick, Rhode Island, United States

Site Status

The Arthritis and Osteoporosis Center

Orangeburg, South Carolina, United States

Site Status

Brown Clinic

Watertown, South Dakota, United States

Site Status

Holston Medical Group

Bristol, Tennessee, United States

Site Status

Tri Cities Medical Research

Bristol, Tennessee, United States

Site Status

Holston Medical Group

Kingsport, Tennessee, United States

Site Status

Galenos Research

Dallas, Texas, United States

Site Status

Benchmark Research

Fort Worth, Texas, United States

Site Status

Team Research of Central Texas

Harker Heights, Texas, United States

Site Status

KRK Medical Research

Richardson, Texas, United States

Site Status

Benchmark Research

San Angelo, Texas, United States

Site Status

Unlimited Research

San Antonio, Texas, United States

Site Status

Texas Medical Research Associates

San Antonio, Texas, United States

Site Status

Clinical Trial Network Oaks Medical Center

Spring, Texas, United States

Site Status

N. Texas Neuro Research

Wichita Falls, Texas, United States

Site Status

Lifetree Clinical Research

Salt Lake City, Utah, United States

Site Status

Dean Medical Center

Oregon, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BUP3015S

Identifier Type: -

Identifier Source: org_study_id